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INTRODUCTION
Anxiety disorders connected with an active lifestyle prompt
some pregnant women to seek for pharmacological intervention
by their obstetricians. Benzodiazepines, especially diazepam,
have been used by obstetrical providers as the major class of
drugs for maternal therapy (1). The pharmacological
intervention is justified because there is an association between
high levels of anxiety during pregnancy and adverse neonatal
outcomes. Premature births as well as low birth weight have
been associated with untreated maternal anxiety during
pregnancy (2). Benzodiazepines are one of the most commonly
used anxiolytics in the world (3). They are prescribed to women
of childbearing age and to pregnant women (4) in order to reduce
stress and manage preeclampsia or eclampsia in the latter part of
pregnancy. Most benzodiazepines diffuse across the placenta (5)
leading to higher fetal levels when compared to levels detected
among pregnant women. There have been concerns regarding
the adverse effects of preservatives used in some preparations,
which could displace bilirubin from albumin leading to
hyperbiliruminemia among infants whose mothers were treated
with diazepam. Moreover, the teratogenicity of benzodiazepines
prescribed during pregnancy have been reviewed (6). When
administered to a pregnant women at or near the time of delivery
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Pregnant women are exposed to benzodiazepines for therapeutic purposes during gestation. The goal of this study was
to evaluate prenatal exposure to benzodiazepines. Time of exposure during course of pregnancy is a significant aspect
of fetal exposure to drugs. Benzodiazepine concentration assay in hair of mothers and newborns exposed prenatally to
these drugs was performed in the studies. Development, validation and evaluation of benzodiazepine determination
method in mothers and their newborns enables assessment of health risks for the child and implementation of adequate
therapeutic procedures. We used A LC-ESI-MS/MS method that allowed determination of diazepam (the main
benzodiazepine used by pregnant women was diazepam) and its metabolites (nordazepam, oxazepam) in hair of mothers
and newborns. LOQ 10 pg/mg of hair was used in the study. Results: concentration of nordazepam was higher than
parent drug (diazepam) and higher in newborns’ hair when compared to mothers’. The mean concentrations of diazepam
in mothers’ hair were 31.6±36.0 and 34.1±42.4 pg/mg in the second and third trimester of pregnancy respectively. The
mean concentration of diazepam in newborns’ hair was higher and reached levels of 53.3±36.5 pg/mg. The mean
concentration of nordazepam in the mothers’ hair corresponding to the second and third trimester was 52.9±48.1 and
89.9±122.8 pg/mg, respectively. Nordazepam in the newborns’ hair was detected at the mean level of 108.1±144.2
pg/mg. It was concluded that diazepam and nordazepam are permanently incorporated into the hair structure. Presence
of diazepam and its metabolites in newborn’s hair confirms that these benzodiazepines permeate placental barrier.
Segmental analysis of mothers’ hair enabled the assessment of drug administration time. Diazepam and its metabolites
determined in hair of newborns may serve as biomarkers of prenatal exposure to these drugs. The performed LC-MS/MS
analysis was accurate enough to determine even low concentrations of benzodiazepines, at the level of few pg/mg of
hair. Levels of diazepam detected in hair of newborns were higher than levels determined in mothers. This may confirm
the fact, that fetus’s ability to metabolize diazepam is scarce. Nordazepam was found in higher concentrations in hair of
newborns than in hair of mothers, which may suggest that it is cumulated in child’s organism. Other metabolites of
diazepam - oxazepam and temazepam - were detected in very few cases, in low concentrations.
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benzodiazepines may cause “the floppy infant syndrome” (6, 7).
Recovery from this condition can last for several hours after
birth (7). Thus, if the use of benzodiazepines is necessary during
pregnancy, the lowest effective dose of the short-active agent
should be established.
There are several methods to determine the levels of
benzodiazepines in hair (8). Most studies focus on the
determination of benzodiazepine levels in adult hair (9);
however, fewer studies have determined these drug levels in
newborn hair. A method that would be suitable for analysis for
both mother’s and newborn’s hair still awaits development and
adoption into clinical or forensic practice. The goal of the study
was to evaluate the prenatal exposure to benzodiazepines based
on the determination of the benzodiazepines levels of maternal
and newborn hair.
MATERIALS AND METHODS
Specimens
Blank dark hair samples for development and validation of a
method were obtained from volunteers who did not take
benzodiazepines, after their verbal consent. An informed consent
for the procedure was obtained from 47 pregnant women at the
Department of Perinatology and Gynecology of the Poznan
University of Medical Sciences in Poznan, who had been
prescribed benzodiazepines by their obstetrician for clinical
anxiety. Samples from mothers and newborns were collected
within 24 hours after delivery. Hair was clipped as close to the
scalp as possible and stored at room temperature. The protocol
for the study was approved by the Bioethics Commission
University of Medical Sciences in Poznan, Poland (No. 387/08,
April 3rd 2008). The study was conducted in compliance with the
Helsinki Declaration (1975 with revision of 2000). Participation
in the study was voluntary.
Hair samples (both for development of the methods and for
experimental use) were decontaminated by subsequent washing
with phosphate buffer pH 7.4 (10 ml) for 5 min, isopropanol (10
ml) for 5 min and methylene chloride (10 ml) for 5 min and dried
in 40°C.
Mother’s hair strands were cut into 3 cm segments,
beginning with the end closest to the scalp and then more cut
more distally which corresponds to the third, second and first
trimester of gestation.
Newborns’ hair samples were not segmented. The maternal
segmented samples and entire sample of newborns’ hair used for
analysis weighed 10±2 mg. Hair were powdered in a ball mill
(Pulverisette 23, Fritsch, Germany) for further analysis.
Chemicals
Acetonitrile, isopropanol, dichloromethane and formic acid
were HPLC grade and purchased from Sigma-Aldrich,
phosphoric buffer was delivered by Merck. Ingredients of
phosphate buffer were purchased from (Polish Chemical
Reagents, POCH, Poland). Diazepam, nordazepam, oxazepam,
temazepam and diazepam-d5 in concentration of 1 mg/ml were
purchased from LGC Standards (Dziekanow, Poland). Drug
“standards” were prepared by dissolving an appropriate mass in
methanol to provide a concentration which was subsequently
diluted to required concentrations. An internal standard (IS)
working solution of the diazepam-d5 was prepared (0.2 µg/ml in
methanol), which was further diluted with methanol to yield
appropriate concentrations to add to samples, calibrators and
quality control samples. Working solutions were stored at 4°C up
to one month.
Sample preparation
The diazepam-d5 20 µl (400 pg/mg) (IS) was added to
approximately 10 mg of powdered hair (calibration, control and
real samples). Next, incubation with 400 µl of phosphate buffer
(pH 7.4) at 50°C was performed overnight. Subsequently,
supernatants were transferred to 2 ml disposable screw top vials
and extracted with 1.2 ml of diisopropyl ether (5 min). After
centrifugation (4000 rpm for 15 min) the organic layer was
collected and evaporated under nitrogen in temp. 40°C. The
residue was reconstituted by adding 50 µl of the mixture of
acetonitrile and water (1:1) with addition of 100 µl/100 ml of
formic acid and 20 µl was injected into the liquid
chromatography-electrospray ionization-tandem mass
spectrometry (LC-ESI-MS/MS) system.
Chromatography and mass spectrometry
Chromatographic separation was performed with Agilent
HP1200 series (Agilent Technologies USA). 20 µl of
reconstituted samples were injected into Zorbax Eclipse XDB-
C18 Rapid Resolution HT 50 ×4.6 mm column. The column was
thermostated at 35°C. Chromatographic run was carried out with
a gradient elution with 0.1% formic acid in water (A) and
acetonitrile (B), at a flow rate of 0.5 mL/min.
A gradient was applied starting with 30% B, maintained by 3
min. and increased to 80% in the next 3 min than kept by 1 min.
From 7 min to 8 min, B was decreased to 30% for stabilization of
mobile phase. A total runtime was 13 min.
Detection was carried out by LC-ESI-MS/MS 6460 Triple
Quad Mass Spectrometer. The instrument was operated in the
positive ionization mode. Instrument sensitivity was optimised
to obtain at least three transitions (MRM). Mass optimiser was
applied for optimisation of fragmentor voltage because of its
greatest impact on sensitivity and fragmentation. The objective
was to find the optimum voltage which provided the strongest
molecular ion and fragment ions.
The optimal parameters of mass spectrometer were: gas
temperature 325°C and gas flow 10 L/min, nebulizer pressure 40
psi, sheath gas temperature 400°C and flow 10 l/min, the
capillary voltage was 400 V. For this parameter optimisation, the
concentration of each benzodiazepine in the standard mixture
was 200 ng/ml.
LC-ESI-MS/MS assay validation
Calibration curves were obtained by preparing spiked blank,
black hair (10 mg) containing final 0, 20, 50, 100, 200, 500
pg/mg of diazepam, nordazepam and oxazepam.
The assessed matrix effect was slightly enhanced for
diazepam (127%±22) and oxazepam (110%±14) and showed no
effect on both compounds. The assessment was performed with
use of Matuszewski et al. method (10).
For the examination of intra-day and inter-day repeatability
(replicate analysis performed per three days) and precision,
control samples with concentration of 20, 100 and 500 pg/mg
and for recovery 20 pg/mg, were prepared using blank hair
spiked with the analytes and real hair samples.
The samples of hair fortified with diazepam, nordazepam and
oxazepam were used for the development and validation of the
quantification procedure for these compounds. In the conditions
provided, a separation of the three quantified compounds occurred.
In order to determine the specificity of the developed method six
blank hair samples were checked for signals interfering with
analytes. Under the chromatographic conditions there were no
interference with analytes by any extractable endogenous material
present in blank hair. Six-point standard curves were prepared by
500
fortifying blank hair with known quantities of studied analytes and
deuterated diazepam and were linear in the studied range for all
benzodiazepines. Correlation coefficients (r) were: 0.997 for
nordazepam, 0.989 oxazepam, and 0.999 for diazepam. High
correlation factors and repeatability confirm the suitability of the
method for chromatographic analysis of compounds of interest in
hair and even in small samples of newborn hair.
The intra-day precision was evaluated by analysis of five
hair samples collected separately from volunteers who did not
take diazepam. The mean values of relative standard deviation
(R.S.D.) are presented in Table 1.
The limits of detection (LOD), which were the lowest
concentrations of drugs at which the signal to noise ratio S/N
was 3 on the similar level of 5 pg/mg for all studied
benzodiazepines. The limit of quantification (LOQ), the lowest
concentration on the calibration curves for all analytes was 10
pg/mg (Table 1). Recovery was in the range 87.5–111.6%.
Statistical analysis
The results are expressed as mean values and standard
deviation. The Student’s T test was used to assess statistical
significance of differences between mean concentrations and
ratios of studied compounds (p<0.05). Correlation between
respective variables were indicated on the base of Pearson
coefficient.
RESULTS
The clinical administered dose of diazepam ranged from 5 to
15 mg per day, and period of administration from 1 to 9 months.
The mean concentration of diazepam in mothers’ hair ranged from
30.8±11.6 pg/mg in the first trimester to 34.1±42.4 pg/mg in the
third trimester. Although the mean concentration of diazepam in
newborns’ hair (53.3±36.5 pg/mg,) was higher than in the samples
of mothers’ hair in the third trimester the differences were not
significant due to high variability of diazepam dosage and
administration time in the group of participating women (Table 2).
The examples of diazepam and its metabolite’s concentrations
in hair of mother and newborn are shown in Fig. 1.
The ratio of concentration (pmol) of the main metabolite of
diazepam-nordazepam in hair of women in the second and third
trimester of gestation was approximately three times higher than
diazepam, while in the hair of newborns it was five-fold higher
than concentration of the parent drug and these differences were
statistically significant (Fig. 2).
DISCUSSION
Currently searching for correlation between mother’s health
problems and medical condition of a child is increasingly
perceived as an important prognostic factor for potential
paediatric therapy. The research involve diseases of genetic
descent and those caused by exposure to xenobiotics such as
drugs or toxins (11, 12). Psychotropic drug use safety during
pregnancy still raises a concern. Studies lack a coherent
approach and uniform methodology, and thus results are often
contradictory (13). Animal studies provide disturbing data
concerning the benzodiazepine treatment in pregnancy, although
they cannot be simply extrapolated to humans due to varying
sample sizes and multiple drug/toxin exposures, which
complicate the interpretation of the results (7). Exposure to high-
dose benzodiazepines in utero has been associated with newborn
withdrawal symptoms, but there is not enough data to confirm
longterm effects of these drugs (14). Retrospective studies can
be biased due to under-reporting of drug consumption by
mothers (15). Further, case reports are influenced by limited
sample sizes. Additionally, numerous factors affecting child
development may further hinder the conclusions in follow-up
studies. Prenatal exposure to legal or illicit drugs can be
examined by determination of their metabolites in different
materials collected before or after delivery (16). The simplest
one is analysis of the newborns’ first urine (reflects the exposure
just before delivery), meconium, amniotic fluid or hair.
Currently hair is the most frequently used material for evaluation
of the prenatal exposure.
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Parameter Concentration[pg/mg] Compound
Diazepam Nordazepam Oxazepam 
20 0.5 21.4 23
100 5 12.1 19Intra-day
precision [RSD]
500 1.4 3.1 8
Recovery [%] 20 111.6 91 87 
LOD [pg/mg]  5 5 5 
LOQ [pg/mg]  10 10 10 
Table 1. Validation parameters of the LC/MS/MS method for benzodiazepines determination.
Period
Mean dose during
period of treatment
[mg/day] 
Length of 
dosing
[months] 
Diazepam 
concentration 
[pg/mg] 
n*
Nordazepam
concentration 
[pg/mg] 
n*
I trimester 2±0.9 30.8±15.3 6 64.5±61.5 4 
II trimester 2±1 31.6±36.0 14 52.9±48.1 17 
III trimester 
7.6±3.6
2.5±0.7 34.1±42.4 26 89.9±122.8 28 
Newborn 53.3±36.5 14 108.1±144.2 27
* – Number of results above LOD.
Table 2. Mean values and standard deviation of dose, administration time of diazepam and diazepam and nordazepam concentration.
The concentration of diazepam in hair of women in our study
was lower than in the study of McClean et al., however in their
study the exact period of drug administration in relationship to
analysis was not described (17). The lack of standardized
techniques in the studies of drug’s adverse effects is one of the
obstacles in establishing fetal exposure. As herein reported,
segmental analysis of mother’s hair and her newborn may be an
acceptable for detection of a biological marker of
benzodiazepine use which remains sensitive weeks after the end
of maternal consumption of these agents. This enables a
cumulative documentation of long term exposure to these
agents. Diagnostic ascertainment is feasible with the use of hair
sampling when the maternal history is neither accurate nor
available. This method has better recovery with similar precision
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Figure 1. Concentration of diazepam and nordiazepam in hair of selected (No 2) women and 
her newborn
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Fig. 1. Concentration of diazepam and
nordazepam in hair of randomly selected
patient (number 2) and her newborn.
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Fig. 2. Ratio of nordazepam/diazepam concentration
(pmol) in hair of mother and newborn.
than method developed by Villain et al., although it has higher
limit of quantification (13). Moreover, a further advantage of the
current method was that only half as many samples were needed
for drug levels determination, important in case of analyzing
biological samples from newborn infants.
Only few studies reported the results of determination of
benzodiazepines in neonatal hair (18, 19). We found that
concentrations of diazepam in the hair of newborns were slightly
higher (not significant) whereas concentrations of nordazepam
were significantly higher than in mother’s hair (p<0.05).
Contact of hair with amniotic fluid should be taken under
consideration during interpretation of results of drugs
determination in newborns’ hair. The most probable time for
contamination of hair by drugs contained in amniotic fluid is the
third trimester. At that time fetal urine and lung fluid secretion
become the two primary sources of amniotic fluid. Analysis of
amniotic fluid for detection of drugs is still a largely unexplored
option. Major studies have been focused on prenatal exposure to
cocaine, in which both parent drugs and metabolites have been
identified with concentrations in the range of nanograms per
milliliter of fluid (20). According to the authors’ best knowledge
there is no data about concentration of benzodiazepines in
amniotic fluid, what makes evaluation of its influence on
concentration in hair impossible.
Studies focused on fetal exposure to benzodiazepines often
lack information on duration and indication for use of
benzodiazepines, medical/obstetric histories and family history,
in addition to the fact that drug use histories from mothers may
be unreliable. These all facts make assessment of risk associated
with benzodiazepine use difficult (13, 21). Thus the analysis of
mother’s and newborn’s hair present a very attractive method for
determination of the drug levels. Further, these data combined
with prospective analysis of the clinical outcomes including
infant follow-up, may permit a better understanding of the
longer term effects on infant development.
There is difference in the benzodiazepines profile in
progression of pregnancy. This difference depends on greater
placental transfer of benzodiazepines in late pregnancy when
compared to early stages. This fact is related to an increased size
of the placenta (up to 12 m2 at the end of pregnancy (22)) and its
lipid content. Additionally, the loss of placental cytotrophoblasts
(23) and enhanced uterine circulation (approximately 10 to 20%
of the maternal cardiac output in late pregnancy (24)) facilitate
the transport of diazepam across the placenta. Diazepam crosses
the placenta via both trans- and extracellular pathways at
maximal or perfusion-limited rate leading to higher levels of the
lipophilic drug in the fetus than in mother, until the
concentrations steady-state is reached (25). Kanto et al.
presented several studies which showed that in both early and
late stages of pregnancy administration of diazepam (single and
repeated dosing) results in elevated levels of diazepam and
nordazepam in the fetus and, subsequently, newborn. Slow
accumulation of diazepam in the fetus and its presence in fetal
tissues even after the end of mother’s therapy (26) might be
caused by higher fetal plasma protein binding levels. Moreover,
maternal protein binding capacity is lower than in the age-
matched non-pregnant women (13). Because of these properties
the total concentration of diazepam may be two-fold higher in
the cord plasma during delivery than in the maternal plasma
(fetomaternal ratio 1.2 to 2) during early pregnancy (26) and at
term (5). Thus, the fetal and neonatal health condition may be
endangered due to diazepam single high intravenous dose or
repeated oral dosing administered to the mother (21, 27) before
labor and delivery.
Neonatologists are concerned about the third trimester fetal
exposure to benzodiazepines and their use during labor because
of effects on the fetus and newborn. It has been reported that
such fetal exposure carries the risk of “the floppy infant
syndrome” or symptoms of withdrawal. These symptoms vary
from mild sedation, hypotonia, and reluctance to suck, to
apnoeic spells, cyanosis, and impaired metabolic responses to
cold stress (28). Pharmacokinetic profile and placental transfer
of the benzodiazepines and their deposition in the neonate
expressly explain long-lasting occurrence of these symptoms -
even several months after exposure (29).
Clinical use of pharmacologic agents during the prenatal
period should always be preceded by safety testing.
Verification of a drug involves preclinical studies including
appropriate toxicological studies as well as appropriately
designed phase III clinical trials. One of the most important
factors characterizing the drug’s features is its
pharmacokinetics which is measurably altered during
pregnancy. As clinicians evaluate the best means of monitoring
the safety and efficacy of therapy (6), the attempt to develop a
suitable method of neonate’s and mother’s hair analysis for
assessment of benzodiazepine exposure level is needed.
We have developed a non-invasive method that can be
applied for evaluation of prenatal exposure to benzodiazepines
in newborns. In our study of 47 mother-newborn pairs,
diazepam and especially the main metabolite of diazepam
(nordazepam) are present in hair of mother and newborn after
anxiety treatment with benzodiazepines during pregnancy. To
expand these preliminary results to a broader population, a
larger experimental group would be needed, but nonetheless
we provide evidence of a sensitive and specific method for
measurement of diazepam and its major metabolite in the hair
of mothers and newborns. This method has both clinical
relevance in neonatal care of children of mothers with a
history of diazepam use during pregnancy and for forensic
purposes. Although psychotropic medication is potentially
toxic to the developing fetus the adverse effects were not well
investigated likely due to the clinical, ethical, and legal
aspects of fetal involvement in research (30). In view of these
facts and based on the obtained results the authors suggest that
the analysis of the mothers’ and/or newborn’s hair might be
sufficient enough for the fetal benzodiazepine exposure
evaluation.
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